How gut bacteria can improve lung cancer treatment with immune therapy
Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer
This study is looking at how certain good bacteria in your gut might help make lung cancer treatments work better, especially a type of therapy called anti-PD-1, and if you join, you could help researchers find out which bacteria are most helpful by providing samples.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10894857 on NIH RePORTER |
What this research studies
This research investigates how certain gut bacteria may enhance the effectiveness of immune therapies for lung cancer, specifically focusing on the immune checkpoint blockade. The study aims to identify specific bacterial species and their products that can improve the body's response to anti-PD-1 immunotherapy. By understanding the mechanisms through which these bacteria operate, researchers hope to develop better predictive markers for treatment success and reduce the risk of autoimmune side effects. Patients may be involved in providing samples to help identify these beneficial microbes.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients undergoing or considering anti-PD-1 immunotherapy.
Not a fit: Patients with lung cancer who are not eligible for immune checkpoint blockade therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for lung cancer patients receiving immune therapy.
How similar studies have performed: Other studies have shown promising results in leveraging gut microbiota to enhance cancer immunotherapy, suggesting this approach may be viable.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Littman, Dan — New York University School of Medicine
- Study coordinator: Littman, Dan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.